What the Study Found (In Plain English)
Published in BMC cancer (2022), this phase iii randomized trial evaluating human clinical outcomes investigated: Some cancers such as sarcomas (bone and soft tissue sarcomas) and adenoid cystic carcinomas are considered as radioresistant to low linear energy transfer radiation (including photons and protons) and may therefore beneficiate from a carbon ion therapy. Key clinical takeaway: Date of registration: July 20, 2016. The posted information will be updated as needed to reflect protocol amendments and study progress.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (BMC cancer, 2022-05-23; Phase III Randomized Trial; Rigor 82/100): Date of registration: July 20, 2016. The posted information will be updated as needed to reflect protocol amendments and study progress.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.